货号:A134996 同义名: AB1010;Masican
Masitinib is an inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | FAK ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Defactinib | ✔ | 99%+ | |||||||||||||||||
NVP-TAE 226 |
++
FAK, IC50: 5.5 nM PYK2, IC50: 3.5 nM |
IGF-1R,Insulin Receptor | 98+% | ||||||||||||||||
PF-573228 |
+
FAK, IC50: 4 nM |
98% | |||||||||||||||||
Solanesol | ✔ | 90% +(HPLC) | |||||||||||||||||
PF-431396 |
++
FAK, IC50: 2 nM PYK2, IC50: 11 nM |
99%+ | |||||||||||||||||
PND-1186 |
++++
FAK, IC50: 1.5 nM |
99%+ | |||||||||||||||||
PF-562271 |
++++
FAK, IC50: 1.5 nM PYK2, IC50: 13 nM |
99%+ | |||||||||||||||||
GSK2256098 |
++++
FAK, Ki: 0.4 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Fyn ↓ ↑ | Lck ↓ ↑ | Lyn ↓ ↑ | Src ↓ ↑ | Yes ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saracatinib |
++
Fyn, IC50: 10 nM |
++++
LCK, IC50: <4 nM |
+++
Lyn, IC50: 5 nM |
++++
c-Src, IC50: 2.7 nM |
99%+ | ||||||||||||||
SU6656 |
+
Fyn, IC50: 170 nM |
+
Lyn, IC50: 130 nM |
+
Src, IC50: 280 nM |
++
YES, IC50: 20 nM |
98% | ||||||||||||||
PP1 |
+++
Fyn, IC50: 6 nM |
+++
LCK, IC50: 5 nM |
EGFR | 99%+ | |||||||||||||||
PP2 |
+++
Fyn, IC50: 5 nM |
++++
LCK, IC50: 4 nM |
98% | ||||||||||||||||
WH-4-023 |
++++
Lck, IC50: 2 nM |
+++
Src, IC50: 6 nM |
99%+ | ||||||||||||||||
NVP-BHG 712 |
+
c-Src, IC50: 1.266 μM |
99%+ | |||||||||||||||||
CCT196969 |
++
LCK, IC50: 0.02 μM |
+
Src, IC50: 0.03 μM |
98% | ||||||||||||||||
MNS |
+
Src, IC50: 29.3 μM |
p97,Syk | 98% | ||||||||||||||||
Tirbanibulin |
++
Src (HuH7), GI50: 13 nM Src (Hep 3B), GI50: 26 nM |
99%+ | |||||||||||||||||
PP121 |
++
Src, IC50: 14 nM |
PDGFR,VEGFR | 99%+ | ||||||||||||||||
Bosutinib |
++++
Src, IC50: 1.2 nM |
99% | |||||||||||||||||
Dasatinib monohydrate |
++++
Src, IC50: 0.8 nM |
98% | |||||||||||||||||
Quercetin | ✔ | Sirtuin,PKC | 97% | ||||||||||||||||
Dasatinib |
++++
Src, IC50: 0.8 nM |
98% | |||||||||||||||||
Repotrectinib |
+++
Src, IC50: 5.3 nM |
99% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | c-Kit ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrphostin AG1296 |
+
c-Kit (Swiss 3T3), IC50: 1.8 μM |
PDGFR | 99%+ | ||||||||||||||||
Masitinib |
+
Kit, IC50: 200 nM |
99%+ | |||||||||||||||||
Motesanib Diphosphate |
+++
Kit, IC50: 8 nM |
98% | |||||||||||||||||
Ki8751 |
++
c-Kit, IC50: 40 nM |
98+% | |||||||||||||||||
Tivozanib |
++
c-Kit, IC50: 78 nM |
99%+ | |||||||||||||||||
Pazopanib |
+
c-Kit, IC50: 140 nM |
99% | |||||||||||||||||
Sitravatinib |
+++
Kit, IC50: 6 nM |
99%+ | |||||||||||||||||
Pexidartinib |
+++
Kit, IC50: 10 nM |
99%+ | |||||||||||||||||
Lactate |
++++
c-Kit, IC50: 2 nM |
FLT3 | 85% | ||||||||||||||||
Amuvatinib |
+++
c-Kit (D816H), IC50: 10 nM |
99%+ | |||||||||||||||||
Imatinib Mesylate |
+
c-Kit, IC50: 100 nM |
PDGFR | 99% | ||||||||||||||||
AZD2932 |
+++
c-Kit, IC50: 9 nM |
98% | |||||||||||||||||
Axitinib |
++++
Kit, IC50: 1.7 nM |
98% | |||||||||||||||||
Dovitinib |
++++
c-Kit, IC50: 2 nM |
FLT3 | 99%+ | ||||||||||||||||
Sunitinib | ✔ | FLT3 | 98% | ||||||||||||||||
OSI-930 |
+
Kit, IC50: 80 nM |
99%+ | |||||||||||||||||
Telatinib |
++++
c-Kit, IC50: 1 nM |
99%+ | |||||||||||||||||
Dasatinib monohydrate |
++
c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM |
Src | 98% | ||||||||||||||||
Dasatinib |
++
c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM |
Src | 98% | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | PDGFR ↓ ↑ | PDGFRα ↓ ↑ | PDGFRβ ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrphostin A9 |
+
PDGFR, IC50: 0.5 μM |
EGFR | 98% | ||||||||||||||||
Tyrphostin AG1296 | 99%+ | ||||||||||||||||||
Motesanib Diphosphate |
++
PDGFR, IC50: 84 nM |
98% | |||||||||||||||||
Pazopanib |
++
PDGFR, IC50: 84 nM |
99% | |||||||||||||||||
Imatinib |
+
PDGFR, IC50: 100 nM |
c-Kit | 98% | ||||||||||||||||
Imatinib Mesylate |
+
PDGFR, IC50: 100 nM |
c-Kit | 99% | ||||||||||||||||
Sennoside B | ✔ | 99%+ | |||||||||||||||||
PP121 |
++++
PDGFR, IC50: 2 nM |
mTOR,VEGFR | 99%+ | ||||||||||||||||
Crenolanib |
++++
PDGFRα, Kd: 2.1 nM |
++++
PDGFRβ, Kd: 3.2 nM |
99%+ | ||||||||||||||||
Masitinib |
+
PDGFRα, IC50: 540 nM |
+
PDGFRβ, IC50: 800 nM |
99%+ | ||||||||||||||||
Ki8751 |
++
PDGFRα, IC50: 67 nM |
c-Kit | 98+% | ||||||||||||||||
Tivozanib |
++
PDGFRα, IC50: 40 nM |
++
PDGFRβ, IC50: 49 nM |
99%+ | ||||||||||||||||
Ponatinib |
++++
PDGFRα, IC50: 1.1 nM |
98% | |||||||||||||||||
Amuvatinib |
++
PDGFRα (V561D), IC50: 40 nM |
99%+ | |||||||||||||||||
Axitinib |
+++
PDGFRα, IC50: 5.0 nM |
++++
PDGFRβ, IC50: 1.6 nM |
98% | ||||||||||||||||
CP-673451 |
+++
PDGFRα, IC50: 10 nM |
++++
PDGFRβ, IC50: 1 nM |
99%+ | ||||||||||||||||
Telatinib |
+++
PDGFRα, IC50: 15 nM |
c-Kit | 99%+ | ||||||||||||||||
Nintedanib |
++
PDGFRα, IC50: 59 nM |
++
PDGFRβ, IC50: 65 nM |
99+% | ||||||||||||||||
Avapritinib |
++++
PDGFRα (D842V), IC50: 0.5 nM |
99%+ | |||||||||||||||||
MK-2461 |
+++
PDGFRβ, IC50: 22 nM |
98%+ | |||||||||||||||||
Lactate |
+++
PDGFRβ, IC50: 27 nM |
c-Kit,FLT3 | 85% | ||||||||||||||||
Linifanib |
++
PDGFRβ, IC50: 66 nM |
99%+ | |||||||||||||||||
AZD2932 |
+++
PDGFRβ, IC50: 4 nM |
c-Kit | 98% | ||||||||||||||||
Dovitinib |
+++
PDGFRβ, IC50: 27 nM |
c-Kit,FLT3 | 99%+ | ||||||||||||||||
Sorafenib |
++
mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM |
99% | |||||||||||||||||
Sunitinib |
++++
PDGFRβ , IC50: 2 nM |
FLT3 | 98% | ||||||||||||||||
Orantinib |
+++
PDGFRβ, Ki: 8 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | FGFR ↓ ↑ | FGFR1 ↓ ↑ | FGFR2 ↓ ↑ | FGFR3 ↓ ↑ | FGFR4 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrphostin AG1296 |
+
FGFR (Swiss 3T3), IC50: 12.3 μM |
PDGFR | 99%+ | ||||||||||||||||
Pazopanib |
+
FGFR, IC50: 140 nM |
99% | |||||||||||||||||
Erdafitinib | ✔ | RET | 99%+ | ||||||||||||||||
Gambogenic acid | ✔ | 98+% | |||||||||||||||||
Sulfatinib |
+++
FGFR1, IC50: 15 nM |
99+% | |||||||||||||||||
Nintedanib esylate |
+
FGFR1, IC50: 69 nM |
++
FGFR2, IC50: 37 nM |
+
FGFR3, IC50: 108 nM |
98% | |||||||||||||||
Zoligratinib |
+++
FGFR1, IC50: 9.3 nM |
+++
FGFR2, IC50: 7.6 nM |
++
FGFR3, IC50: 22 nM |
+
FGFR4, IC50: 290 nM |
99%+ | ||||||||||||||
MK-2461 |
+
FGFR1, IC50: 65 nM |
++
FGFR2, IC50: 39 nM |
++
FGFR3, IC50: 50 nM |
98%+ | |||||||||||||||
SU 5402 |
++
FGFR1, IC50: 30 nM |
98% | |||||||||||||||||
Brivanib |
+
FGFR1, IC50: 148 nM |
99%+ | |||||||||||||||||
Lucitanib |
++
FGFR1, IC50: 17.5 nM |
+
FGFR2, IC50: 82.5 nM |
99%+ | ||||||||||||||||
Ponatinib |
++++
FGFR1, IC50: 2.2 nM |
98% | |||||||||||||||||
PD-166866 |
+
FGFR1, IC50: 52.4 nM |
98% | |||||||||||||||||
Narazaciclib |
++
FGFR1, IC50: 26 nM |
RET | 99%+ | ||||||||||||||||
Lactate |
+++
FGFR1, IC50: 8 nM |
+++
FGFR3, IC50: 9 nM |
c-Kit,FLT3 | 85% | |||||||||||||||
Lenvatinib mesylate |
++
FGFR1, IC50: 46 nM |
c-RET | 99% | ||||||||||||||||
LY2874455 |
++++
FGFR1, IC50: 2.8 nM |
++++
FGFR2, IC50: 2.6 nM |
+++
FGFR3, IC50: 6.4 nM |
+++
FGFR4, IC50: 6 nM |
99%+ | ||||||||||||||
FIIN-2 |
+++
FGFR1, IC50: 3.09 nM |
+++
FGFR2, IC50: 4.3 nM |
++
FGFR3, IC50: 27 nM |
++
FGFR4, IC50: 45.3 nM |
98% | ||||||||||||||
FIIN-3 |
+++
FGFR1, IC50: 13.1 nM |
++
FGFR2, IC50: 21 nM |
++
FGFR3, IC50: 31.4 nM |
++
FGFR4, IC50: 35.3 nM |
98% | ||||||||||||||
Infigratinib |
++++
FGFR1, IC50: 0.9 nM |
++++
FGFR2, IC50: 1.4 nM |
++++
FGFR3, IC50: 1.0 nM FGFR3 (K650E), IC50: 4.9 nM |
+
FGFR4, IC50: 60 nM |
99%+ | ||||||||||||||
Danusertib |
++
FGFR1, IC50: 47 nM |
RET | 99%+ | ||||||||||||||||
R1530 |
++
FGFR1, IC50: 28 nM |
98% | |||||||||||||||||
ENMD-2076 |
+
FGFR1, IC50: 92.7 nM |
+
FGFR2, IC50: 70.8 nM |
RET,FLT3 | 98% | |||||||||||||||
Dovitinib |
+++
FGFR1, IC50: 8 nM |
+++
FGFR3, IC50: 9 nM |
c-Kit,FLT3 | 99%+ | |||||||||||||||
Sorafenib |
+
FGFR1, IC50: 580 nM |
99% | |||||||||||||||||
SSR128129E |
+
FGFR1, IC50: 1.9 μM |
99%+ | |||||||||||||||||
AZD-4547 |
++++
FGFR1, IC50: 0.2 nM |
++++
FGFR2, IC50: 2.5 nM |
++++
FGFR3, IC50: 1.8 nM |
98% | |||||||||||||||
Lenvatinib |
++
FGFR1, IC50: 46 nM |
RET | 98% | ||||||||||||||||
PD173074 |
++
FGFR1, IC50: ~25 nM |
99%+ | |||||||||||||||||
S49076 |
++
FGFR1, IC50: 18 nM |
+++
FGFR2, IC50: 17 nM |
+++
FGFR3, IC50: 15 nM |
98% | |||||||||||||||
Futibatinib |
++++
FGFR1, IC50: 1.8 nM |
++++
FGFR2, IC50: 1.4 nM |
++++
FGFR3, IC50: 1.6 nM |
+++
FGFR4, IC50: 3.7 nM |
99%+ | ||||||||||||||
Ferulic Acid |
+
FGFR1, IC50: 3.78 μM |
+
FGFR2, IC50: 12.5 μM |
98% | ||||||||||||||||
Nintedanib |
+
FGFR1, IC50: 69 nM |
++
FGFR2, IC50: 37 nM |
+
FGFR3, IC50: 108 nM |
+
FGFR4, IC50: 610 nM |
99+% | ||||||||||||||
ASP5878 |
++++
FGFR1, IC50: 0.47 nM |
++++
FGFR2, IC50: 0.6 nM |
++++
FGFR3, IC50: 0.74 nM |
+++
FGFR4, IC50: 3.5 nM |
98% | ||||||||||||||
PRN1371 |
++++
FGFR1, IC50: 0.6 nM |
++++
FGFR2, IC50: 1.3 nM |
+++
FGFR3, IC50: 4.1 nM |
++
FGFR4, IC50: 19.3 nM |
99% | ||||||||||||||
Derazantinib |
+++
FGFR1, IC50: 4.5 nM |
++++
FGFR2, IC50: 1.8 nM |
+++
FGFR3, IC50: 4.5 nM |
++
FGFR4, IC50: 34 nM |
RET | 99%+ | |||||||||||||
ODM-203 |
+++
FGFR1, IC50: 11 nM |
+++
FGFR2, IC50: 16 nM |
+++
FGFR3, IC50: 6 nM |
++
FGFR4, IC50: 35 nM |
99%+ | ||||||||||||||
Pemigatinib |
++++
FGFR1, IC50: 0.4 nM |
++++
FGFR2, IC50: 0.5 nM |
++++
FGFR3, IC50: 1.2 nM |
++
FGFR4, IC50: 30 nM |
99%+ | ||||||||||||||
SKLB 610 | ✔ | PDGFR | 99%+ | ||||||||||||||||
Alofanib | ✔ | 99%+ | |||||||||||||||||
Lirafugratinib | ✔ | 98% | |||||||||||||||||
Masitinib mesylate | ✔ | FAK | 99%+ | ||||||||||||||||
BLU9931 |
+
FGFR3, IC50: 150 nM |
+++
FGFR4, IC50: 3 nM |
99%+ | ||||||||||||||||
BO-264 | ✔ | 99%+ | |||||||||||||||||
Fisogatinib |
+++
FGFR4, IC50: 5 nM |
99%+ | |||||||||||||||||
H3B-6527 |
++++
FGFR4, IC50: <1.2 nM |
99%+ | |||||||||||||||||
Roblitinib |
++++
FGFR4, IC50: 1.9 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Masitinib is an inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00831922 | Rheumatoid Arthritis | Phase 2 | Completed | - | - |
NCT00831974 | Mastocytosis | Phase 2 | Completed | - | - |
NCT01045577 | Psoriasis | Phase 2 | Completed | - | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.01mL 0.40mL 0.20mL |
10.03mL 2.01mL 1.00mL |
20.05mL 4.01mL 2.01mL |
CAS号 | 790299-79-5 |
分子式 | C28H30N6OS |
分子量 | 498.642 |
别名 | AB1010;Masican;Masivet.;Masitinib. Brand name: Kinavet;Masiviera |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,2-8°C |
溶解度 |
DMSO: 105 mg/mL(210.57 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |